Company Overview
Snapshot
Founded in January 2001 by Lior Carmon, CureTech operated with 51–200 employees. The company raised $4 million across one funding round. A significant milestone occurred in March 2018 when InSight Innovations acquired CureTech for up to $550 million.
Business overview
CureTech was a biotechnology company focused on developing broad-spectrum, immune-modulating products for cancer treatment and control. Its product line included antibodies and peptide-based vaccines designed to modulate the immune response to exert anti-cancer activity. The company's lead humanized antibody product, pidilizumab (CT-011), was in Phase II clinical testing, showing promising results in attenuating tumor growth and eliminating tumor metastases. CureTech operated within the pharmaceuticals sector, serving the healthcare and life sciences markets.
Strategic signal
In February 2020, news reports indicated that CureTech's operations ceased due to insolvency, marking the end of its cancer-fighting initiatives. This development followed a period of uncertainty, including a canceled acquisition deal with InSight Innovations in July 2018, which led to cost-cutting measures. The insolvency signals a significant setback for the company's therapeutic pipeline and highlights the inherent risks in the biotechnology sector, particularly for firms reliant on clinical trial success and acquisition outcomes.
Log in to access full profile ›Company Intelligence Q&A
- What was CureTech's primary focus?
- CureTech was a biotechnology company developing broad-spectrum, immune-modulating products for the treatment and control of cancer, including antibodies and peptide-based vaccines.
- What was the status of CureTech's lead product, pidilizumab?
- CureTech's lead humanized antibody product, pidilizumab (CT-011), was in Phase II clinical testing and had shown promising results in attenuating tumor growth and eliminating tumor metastases.
- When did Medivation enter a licensing agreement with CureTech?
- In December 2014, Medivation took up a $335 million licensing option for further development and commercialization of pidilizumab from CureTech.
- What was the outcome of the acquisition attempt by InSight Innovations?
- In March 2018, InSight Innovations acquired CureTech for up to $550 million. However, by July 2018, the acquisition deal was canceled, leading to cost-cutting at CureTech.
- What was the ultimate fate of CureTech?
- In February 2019, CureTech ceased to operate, with news reports in February 2020 confirming the company's insolvency, ending its cancer-fighting initiatives.